Skip to main content
NCBI home page
Postgraduate Medical Journal logoLink to Postgraduate Medical Journal
. 2003 Apr;79(930):206–213. doi: 10.1136/pmj.79.930.206

Acute glomerulonephritis

C Vinen 1, D Oliveira 1
PMCID: PMC1742671  PMID: 12743337

Full Text

The Full Text of this article is available as a PDF (169.2 KB).

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Baldwin D. S., Gluck M. C., Lowenstein J., Gallo G. R. Lupus nephritis. Clinical course as related to morphologic forms and their transitions. Am J Med. 1977 Jan;62(1):12–30. doi: 10.1016/0002-9343(77)90345-x. [DOI] [PubMed] [Google Scholar]
  2. Boumpas D. T., Austin H. A., 3rd, Fessler B. J., Balow J. E., Klippel J. H., Lockshin M. D. Systemic lupus erythematosus: emerging concepts. Part 1: Renal, neuropsychiatric, cardiovascular, pulmonary, and hematologic disease. Ann Intern Med. 1995 Jun 15;122(12):940–950. doi: 10.7326/0003-4819-122-12-199506150-00009. [DOI] [PubMed] [Google Scholar]
  3. Campise M., Tarantino A. Glomerulonephritis in mixed cryoglobulinaemia: what treatment? Nephrol Dial Transplant. 1999 Feb;14(2):281–283. doi: 10.1093/ndt/14.2.281. [DOI] [PubMed] [Google Scholar]
  4. Cattran D. C., Greenwood C., Ritchie S. Long-term benefits of angiotensin-converting enzyme inhibitor therapy in patients with severe immunoglobulin a nephropathy: a comparison to patients receiving treatment with other antihypertensive agents and to patients receiving no therapy. Am J Kidney Dis. 1994 Feb;23(2):247–254. doi: 10.1016/s0272-6386(12)80980-2. [DOI] [PubMed] [Google Scholar]
  5. Chan T. M., Li F. K., Tang C. S., Wong R. W., Fang G. X., Ji Y. L., Lau C. S., Wong A. K., Tong M. K., Chan K. W. Efficacy of mycophenolate mofetil in patients with diffuse proliferative lupus nephritis. Hong Kong-Guangzhou Nephrology Study Group. N Engl J Med. 2000 Oct 19;343(16):1156–1162. doi: 10.1056/NEJM200010193431604. [DOI] [PubMed] [Google Scholar]
  6. Couser W. G. Glomerulonephritis. Lancet. 1999 May 1;353(9163):1509–1515. doi: 10.1016/S0140-6736(98)06195-9. [DOI] [PubMed] [Google Scholar]
  7. D'Amico G. Clinical features and natural history in adults with IgA nephropathy. Am J Kidney Dis. 1988 Nov;12(5):353–357. doi: 10.1016/s0272-6386(88)80023-4. [DOI] [PubMed] [Google Scholar]
  8. D'Amico G., Fornasieri A. Cryoglobulinemic glomerulonephritis: a membranoproliferative glomerulonephritis induced by hepatitis C virus. Am J Kidney Dis. 1995 Mar;25(3):361–369. doi: 10.1016/0272-6386(95)90095-0. [DOI] [PubMed] [Google Scholar]
  9. D'Amico G. Natural history of idiopathic IgA nephropathy: role of clinical and histological prognostic factors. Am J Kidney Dis. 2000 Aug;36(2):227–237. doi: 10.1053/ajkd.2000.8966. [DOI] [PubMed] [Google Scholar]
  10. Daghestani L., Pomeroy C. Renal manifestations of hepatitis C infection. Am J Med. 1999 Mar;106(3):347–354. doi: 10.1016/s0002-9343(99)00014-5. [DOI] [PubMed] [Google Scholar]
  11. Davin J. C., Ten Berge I. J., Weening J. J. What is the difference between IgA nephropathy and Henoch-Schönlein purpura nephritis? Kidney Int. 2001 Mar;59(3):823–834. doi: 10.1046/j.1523-1755.2001.059003823.x. [DOI] [PubMed] [Google Scholar]
  12. Donaghy M., Rees A. J. Cigarette smoking and lung haemorrhage in glomerulonephritis caused by autoantibodies to glomerular basement membrane. Lancet. 1983 Dec 17;2(8364):1390–1393. doi: 10.1016/s0140-6736(83)90923-6. [DOI] [PubMed] [Google Scholar]
  13. Emancipator S. N. IgA nephropathy: morphologic expression and pathogenesis. Am J Kidney Dis. 1994 Mar;23(3):451–462. doi: 10.1016/s0272-6386(12)81011-0. [DOI] [PubMed] [Google Scholar]
  14. Floege J., Feehally J. IgA nephropathy: recent developments. J Am Soc Nephrol. 2000 Dec;11(12):2395–2403. doi: 10.1681/ASN.V11122395. [DOI] [PubMed] [Google Scholar]
  15. Galla J. H. IgA nephropathy. Kidney Int. 1995 Feb;47(2):377–387. doi: 10.1038/ki.1995.50. [DOI] [PubMed] [Google Scholar]
  16. Goldstein A. R., White R. H., Akuse R., Chantler C. Long-term follow-up of childhood Henoch-Schönlein nephritis. Lancet. 1992 Feb 1;339(8788):280–282. doi: 10.1016/0140-6736(92)91341-5. [DOI] [PubMed] [Google Scholar]
  17. Gourley M. F., Austin H. A., 3rd, Scott D., Yarboro C. H., Vaughan E. M., Muir J., Boumpas D. T., Klippel J. H., Balow J. E., Steinberg A. D. Methylprednisolone and cyclophosphamide, alone or in combination, in patients with lupus nephritis. A randomized, controlled trial. Ann Intern Med. 1996 Oct 1;125(7):549–557. doi: 10.7326/0003-4819-125-7-199610010-00003. [DOI] [PubMed] [Google Scholar]
  18. Hricik D. E., Chung-Park M., Sedor J. R. Glomerulonephritis. N Engl J Med. 1998 Sep 24;339(13):888–899. doi: 10.1056/NEJM199809243391306. [DOI] [PubMed] [Google Scholar]
  19. Jayne D. R., Marshall P. D., Jones S. J., Lockwood C. M. Autoantibodies to GBM and neutrophil cytoplasm in rapidly progressive glomerulonephritis. Kidney Int. 1990 Mar;37(3):965–970. doi: 10.1038/ki.1990.72. [DOI] [PubMed] [Google Scholar]
  20. Jindal K. K. Management of idiopathic crescentic and diffuse proliferative glomerulonephritis: evidence-based recommendations. Kidney Int Suppl. 1999 Jun;70:S33–S40. doi: 10.1046/j.1523-1755.1999.07005.x. [DOI] [PubMed] [Google Scholar]
  21. Johnson R. J., Lovett D., Lehrer R. I., Couser W. G., Klebanoff S. J. Role of oxidants and proteases in glomerular injury. Kidney Int. 1994 Feb;45(2):352–359. doi: 10.1038/ki.1994.45. [DOI] [PubMed] [Google Scholar]
  22. Johnson R. J., Willson R., Yamabe H., Couser W., Alpers C. E., Wener M. H., Davis C., Gretch D. R. Renal manifestations of hepatitis C virus infection. Kidney Int. 1994 Nov;46(5):1255–1263. doi: 10.1038/ki.1994.393. [DOI] [PubMed] [Google Scholar]
  23. Kaku Y., Nohara K., Honda S. Renal involvement in Henoch-Schönlein purpura: a multivariate analysis of prognostic factors. Kidney Int. 1998 Jun;53(6):1755–1759. doi: 10.1046/j.1523-1755.1998.00915.x. [DOI] [PubMed] [Google Scholar]
  24. Kalluri R., Wilson C. B., Weber M., Gunwar S., Chonko A. M., Neilson E. G., Hudson B. G. Identification of the alpha 3 chain of type IV collagen as the common autoantigen in antibasement membrane disease and Goodpasture syndrome. J Am Soc Nephrol. 1995 Oct;6(4):1178–1185. doi: 10.1681/ASN.V641178. [DOI] [PubMed] [Google Scholar]
  25. Kashgarian M. Lupus nephritis: lessons from the path lab. Kidney Int. 1994 Mar;45(3):928–938. doi: 10.1038/ki.1994.123. [DOI] [PubMed] [Google Scholar]
  26. Kluth D. C., Rees A. J. Anti-glomerular basement membrane disease. J Am Soc Nephrol. 1999 Nov;10(11):2446–2453. doi: 10.1681/ASN.V10112446. [DOI] [PubMed] [Google Scholar]
  27. Levy J. B., Pusey C. D. Still a role for plasma exchange in rapidly progressive glomerulonephritis? J Nephrol. 1997 Jan-Feb;10(1):7–13. [PubMed] [Google Scholar]
  28. Levy J. New aspects in the management of ANCA-positive vasculitis. Nephrol Dial Transplant. 2001 Jul;16(7):1314–1317. doi: 10.1093/ndt/16.7.1314. [DOI] [PubMed] [Google Scholar]
  29. Lewy J. E., Salinas-Madrigal L., Herdson P. B., Pirani C. L., Metcoff J. Clinico-pathologic correlations in acute poststreptococcal glomerulonephritis. A correlation between renal functions, morphologic damage and clinical course of 46 children with acute poststreptococcal glomerulonephritis. Medicine (Baltimore) 1971 Nov;50(6):453–501. [PubMed] [Google Scholar]
  30. Madaio M. P., Harrington J. T. The diagnosis of glomerular diseases: acute glomerulonephritis and the nephrotic syndrome. Arch Intern Med. 2001 Jan 8;161(1):25–34. doi: 10.1001/archinte.161.1.25. [DOI] [PubMed] [Google Scholar]
  31. McIntyre C. W., Fluck R. J., Lambie S. H. Steroid and cyclophosphamide therapy for IgA nephropathy associated with crescenteric change: an effective treatment. Clin Nephrol. 2001 Sep;56(3):193–198. [PubMed] [Google Scholar]
  32. Merkel F., Pullig O., Marx M., Netzer K. O., Weber M. Course and prognosis of anti-basement membrane antibody (anti-BM-Ab)-mediated disease: report of 35 cases. Nephrol Dial Transplant. 1994;9(4):372–376. [PubMed] [Google Scholar]
  33. Mokrzycki M. H., Kaplan A. A. Therapeutic plasma exchange: complications and management. Am J Kidney Dis. 1994 Jun;23(6):817–827. doi: 10.1016/s0272-6386(12)80135-1. [DOI] [PubMed] [Google Scholar]
  34. Nolin L., Courteau M. Management of IgA nephropathy: evidence-based recommendations. Kidney Int Suppl. 1999 Jun;70:S56–S62. doi: 10.1046/j.1523-1755.1999.07008.x. [DOI] [PubMed] [Google Scholar]
  35. Nowack R., Birck R., van der Woude F. J. Mycophenolate mofetil for systemic vasculitis and IgA nephropathy. Lancet. 1997 Mar 15;349(9054):774–774. doi: 10.1016/S0140-6736(05)60198-5. [DOI] [PubMed] [Google Scholar]
  36. Oliveira D. B. Poststreptococcal glomerulonephritis: getting to know an old enemy. Clin Exp Immunol. 1997 Jan;107(1):8–10. doi: 10.1046/j.1365-2249.1997.d01-898.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  37. Peake P. W., Pussell B. A., Karplus T. E., Riley E. H., Charlesworth J. A. Post-streptococcal glomerulonephritis: studies on the interaction between nephritis strain-associated protein (NSAP), complement and the glomerulus. APMIS. 1991 May;99(5):460–466. doi: 10.1111/j.1699-0463.1991.tb05176.x. [DOI] [PubMed] [Google Scholar]
  38. Potter E. V., Lipschultz S. A., Abidh S., Poon-King T., Earle D. P. Twelve to seventeen-year follow-up of patients with poststreptococcal acute glomerulonephritis in Trinidad. N Engl J Med. 1982 Sep 16;307(12):725–729. doi: 10.1056/NEJM198209163071205. [DOI] [PubMed] [Google Scholar]
  39. Ruggenenti P., Schieppati A., Remuzzi G. Progression, remission, regression of chronic renal diseases. Lancet. 2001 May 19;357(9268):1601–1608. doi: 10.1016/S0140-6736(00)04728-0. [DOI] [PubMed] [Google Scholar]
  40. Schacht R. G., Gluck M. C., Gallo G. R., Baldwin D. S. Progression to uremia after remission of acute poststreptococcal glomerulonephritis. N Engl J Med. 1976 Oct 28;295(18):977–981. doi: 10.1056/NEJM197610282951803. [DOI] [PubMed] [Google Scholar]
  41. Tejani A., Ingulli E. Poststreptococcal glomerulonephritis. Current clinical and pathologic concepts. Nephron. 1990;55(1):1–5. doi: 10.1159/000185909. [DOI] [PubMed] [Google Scholar]
  42. Tipping P. G., Kitching A. R., Cunningham M. A., Holdsworth S. R. Immunopathogenesis of crescentic glomerulonephritis. Curr Opin Nephrol Hypertens. 1999 May;8(3):281–286. doi: 10.1097/00041552-199905000-00002. [DOI] [PubMed] [Google Scholar]
  43. Yoshikawa N., Ito H., Sakai T., Takekoshi Y., Honda M., Awazu M., Ito K., Iitaka K., Koitabashi Y., Yamaoka K. A controlled trial of combined therapy for newly diagnosed severe childhood IgA nephropathy. The Japanese Pediatric IgA Nephropathy Treatment Study Group. J Am Soc Nephrol. 1999 Jan;10(1):101–109. doi: 10.1681/ASN.V101101. [DOI] [PubMed] [Google Scholar]

Articles from Postgraduate Medical Journal are provided here courtesy of BMJ Publishing Group

RESOURCES